The initial public offering (IPO) of Emcure Pharmaceuticals got off to a lukewarm start on July 3rd,
the first day of bidding. Here’s a breakdown of the subscription data.
Overall Subscription Ratio: 0.29 times, meaning bids were received for only 29% of the shares offered.
Non-institutional Investors: Most active category, subscribing to 40% of their allotted quota.
Retail Investors: Subscribed to 38% of their reserved portion.
Employees: Showed the strongest interest, subscribing to 81% of their quota.
